The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany

被引:22
|
作者
Peri, Rosemarie [1 ,2 ]
Aguilar, Rebeca Cruz [1 ,2 ]
Tueffers, Kester [3 ]
Erhardt, Andreas [4 ]
Link, Alexander [5 ]
Ehlermann, Philipp [6 ]
Angeli, Wolfgang [7 ]
Frank, Thorsten [8 ]
Storr, Martin [9 ,10 ]
Gluck, Thomas [11 ]
Sturm, Andreas [12 ]
Rosien, Ulrich [13 ]
Tacke, Frank [14 ]
Bachmann, Oliver [15 ,16 ]
Solbach, Philipp [15 ,16 ]
Stallmach, Andreas [17 ]
Goeser, Felix [2 ,18 ]
Vehreschild, Maria J. G. T. [1 ,2 ,19 ]
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] German Ctr Infect Res DZIF, Bonn, Germany
[3] St Johannes Hosp, Dept Internal Med 2, Dortmund, Germany
[4] St Petrus Hosp, Dept Internal Med 2, Wuppertal, Germany
[5] Univ Hosp Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany
[6] SRH Kurpfalzkrankenhaus Heidelberg, Dept Internal Med, Heidelberg, Germany
[7] Kempten Oberallgau Clin, Dept Gastroenterol, Kempten, Germany
[8] St Katharinen Hosp, Dept Internal Med 2, Frechen, Germany
[9] Ludwig Maximilians Univ Munchen, Dept Gastroenterol, Munich, Germany
[10] Ctr Endoscopy, Starnberg, Germany
[11] Trostberg Clin, Dept Internal Med, Trostberg, Germany
[12] DRK Kliniken Westend, Dept Internal Med & Gastroenterol, Berlin, Germany
[13] Israelit Hosp Hamburg, Visceral Med Ctr, Hamburg, Germany
[14] Univ Hosp Aachen, Dept Med 3, Aachen, Germany
[15] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[16] German Ctr Infect Res DZIF, Hannover, Germany
[17] Univ Hosp Jena, Dept Internal Med Gastroenterol Hepatol & Infecti, Jena, Germany
[18] Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany
[19] Univ Hosp Frankfurt, Dept Internal Med Infect Dis, Frankfurt, Germany
关键词
Fecal microbiota transfer; recurrent Clostridioides difficile infection; microbiota; risk factors; TRANSPLANTATION; PREDICTORS; EFFICACY; FAILURE; SOCIETY;
D O I
10.1177/2050640619839918
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Fecal microbiota transfer (FMT) is highly effective in the treatment and prevention of recurrent Clostridioides difficile infection (rCDI) with cure rates of about 80% after a single treatment. Nevertheless, the reasons for failure in the remaining 20% remain largely elusive. The aim of the present study was to investigate different potential clinical predictors of response to FMT in Germany. Methods Information was extracted from the MicroTrans Registry (NCT02681068), a retrospective observational multicenter study, collecting data from patients undergoing FMT for recurrent or refractory CDI in Germany. We performed binary logistic regression with the following covariates: age, gender, ribotype 027, Eastern Co-operative Oncology Group score, immunosuppression, preparation for FMT by use of proton pump inhibitor, antimotility agents and bowel lavage, previous recurrences, severity of CDI, antibiotic induction treatment, fresh or frozen FMT preparation, and route of application. Results Treatment response was achieved in 191/240 evaluable cases (79.6%) at day 30 (D30) post FMT and 78.1% at day 90 (D90) post FMT. Assessment of clinical predictors for FMT failure by forward and confirmatory backward-stepwise regression analysis yielded higher age as an independent predictor of FMT failure (p = 0.001; OR 1.060; 95%CI 1.025-1.097). Conclusion FMT in Germany is associated with high cure rates at D30 and D90. No specific pre-treatment, preparation or application strategy had an impact on FMT success. Only higher age was identified as an independent risk factor for treatment failure. Based on these and external findings, future studies should focus on the assessment of microbiota and microbiota-associated metabolites as factors determining FMT success.
引用
收藏
页码:716 / 722
页数:7
相关论文
共 50 条
  • [1] Clinical effectiveness of bidirectional fecal microbiota transfer in the treatment of recurrent Clostridioides difficile infections
    Bestfater, Christian
    Vehreschild, Maria J. G. T.
    Stallmach, Andreas
    Tueffers, Kester
    Erhardt, Andreas
    Frank, Thorsten
    Glueck, Thomas
    Goeser, Felix
    Sellge, Gernot
    Solbach, Philipp
    Eisenlohr, Herbert
    Storr, Martin
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (06) : 706 - 711
  • [2] Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection
    Voth, Elida
    Khanna, Sahil
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (07) : 669 - 676
  • [3] Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond
    Kumar, Vinod
    Fischer, Monika
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 73 - 81
  • [4] Fecal microbiota transplantation for recurrent Clostridioides difficile infection
    Haber, Stacy L.
    Raney, Carrington R. K.
    Larson, Trent L.
    Lau, Jennifer Park
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (13) : 935 - 942
  • [5] Impact of Fecal Microbiota Transplant Formulations, Storage Conditions, and Duration on Bacterial Viability, Functionality, and Clinical Outcomes in Patients with Recurrent Clostridioides difficile Infection
    Shaheen, Mohamed
    Mcdougall, Chelsea
    Chan, Leona
    Franz, Rose
    Wong, Karen
    Giebelhaus, Ryland T.
    Nguyen, Gwen
    Nam, Seo Lin
    de la Mata, A. Paulina
    Yeo, Sam
    Harynuk, James J.
    Pakpour, Sepideh
    Xu, Huiping
    Kao, Dina
    MICROORGANISMS, 2025, 13 (03)
  • [6] Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
    Yoon, Hyuk
    Shim, Hyun Ik
    Seol, Mijin
    Shin, Cheol Min
    Park, Young Soo
    Kim, Nayoung
    Lee, Dong Ho
    GUT AND LIVER, 2021, 15 (01) : 61 - 69
  • [7] Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
    Sandhu, Avnish
    Chopra, Teena
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [8] A review of fecal microbiota, live-js']jslm for the prevention of recurrent Clostridioides difficile infection
    Hunt, Aaron
    Drwiega, Emily
    Wang, Yifan
    Danziger, Larry
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (15) : e402 - e411
  • [9] New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation
    Bratkovic, Tomaz
    Zahirovic, Abida
    Bizjak, Marusa
    Rupnik, Maja
    Strukelj, Borut
    Berlec, Ales
    GUT MICROBES, 2024, 16 (01)
  • [10] Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
    Benech, Nicolas
    Barbut, Frederic
    Fitzpatrick, Fidelma
    Krutova, Marcela
    Davies, Kerrie
    Druart, Celine
    Cordaillat-Simmons, Magali
    Heritage, John
    Guery, Benoit
    Kuijper, Ed
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (04) : 462 - 468